Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 17, 2011

Primary Completion Date

March 6, 2013

Study Completion Date

March 6, 2013

Conditions
Pompe Disease
Interventions
BIOLOGICAL

BMN 701

GILT-tagged recombinant human GAA

Trial Locations (10)

5006

Royal Adelaide Hospital, SA Pathology, Adelaide

32610

University of Florida College of Medicine, Gainesville

55131

Zentrum für Kinder- und Jugenmedizin, Mainz

66160

University of Kansas Medical Center, Kansas City

75651

Hôpital Pitié-Salpêtrière, Paris

92103-8765

Univ of California San Diego School of Medicine, La Jolla

06202

Hôpital de I´Archet- Centre Hospitalier Universitaire Nice, Nice

B15 2TH

Old Queen Elizabeth Hospital, Department of Medicine, Birmingham

NW3 2QG

Royal Free Hospital, London

M6 8HD

Salford Royal Hospital NHS Trust, Salford

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY